Alcohol

More documents

Recommendations

Info

Medications • Nicotine Nicotine patch, gum, nasal spray Bupropion Varenicline Rimonabant* • Opiates Methadone Buprenorphine Naltrexone • Stimulants Modafinil Topiramate Baclofen Disulfiram Propranolol Vigabatrin (clinical trials) • <strong>Alcohol</strong> Disulfiram Naltrexone Acamprosate Topiramate
Penn/VA Center Team Joe Volpicelli Wade Berrettini John Cacciola Anna Rose Childress James Cornish Charles Dackis Ronald Ehrman Teresa Franklin Kyle Kampman James McKay A. Thomas McLellan David Metzger David Oslin Helen Pettinati Michael Stromberg Elmer Yu George Woody Arthur Alterman
Page 1 and 2:
The Path to Genomic Medicine For Ad
Page 3 and 4:
Use Use Use Use Use Abuse (declarat
Page 5 and 6:
Possible Changes • Addiction inst
Page 7 and 8:
Addiction: Loss of control • Jean
Page 9 and 10:
Possible Families of Risk Factors
Page 11 and 12:
Response • Genetically influenced
Page 13 and 14:
Drugs of Abuse all Activate Reward
Page 15 and 16:
Effects of Drugs on Dopamine Levels
Page 17 and 18:
Relationship between Cue-Induced De
Page 19:
“Unseen” Reward Cues activate a
Page 22 and 23:
Alcoholism: FDA Approved Medication
Page 24 and 25:
Alcohol - Beverage Condition Cingul
Page 26 and 27:
Baclofen blunts Amygdala Connectivi
Page 28 and 29:
Alcohol reward Sedating drug, facil
Page 30 and 31:
True Translational Story: Naltrexon
Page 32:
Naltrexone decreases Alcohol prefer
Page 38 and 39:
Ethanol Responses Saline 80 70 60 5
Page 40 and 41:
Naltrexone Concurrently Antagonizes
Page 42 and 43:
Brain Reward System Nucleus Accumbe
Page 44 and 45: Dopamine Opioid Antagonism Dopamine
Page 46 and 47: Propose an RCT of an opiate antagon
Page 48 and 49: Naltrexone Affinity at Opioid Recep
Page 50 and 51: Receptor Blockade with Naltrexone i
Page 52 and 53: Post-Docs Tom Aronson, MD Joseph Vo
Page 54 and 55: Pharmacological Treatments for Alco
Page 56 and 57: Days Drinking 1.0 0.8 0.6 0.4 0.2 0
Page 58 and 59: Alcohol Relapse A. coming to treatm
Page 60 and 61: Rates of Never Relapsing According
Page 62 and 63: Blood Alcohol levels (g/dl) 0.1 0.0
Page 64 and 65: Studies supporting efficacy Studies
Page 66 and 67: Baseline Craving Scores % Days Heav
Page 68 and 69: Baseline b-Endorphin Levels in Low-
Page 70 and 71: Key effect: Sensitivity of Endogeno
Page 72 and 73: BAES Stimulation Scores Among FH+ a
Page 74 and 75: Human Mu Opioid Receptor Gene PROMO
Page 76 and 77: Alcohol effects by genotype 50 45 4
Page 78 and 79: Lotsch et al, 2006
Page 80 and 81: Ethnicity & A118G Allele Frequency
Page 82 and 83: Subjective “high” in Naltrexone
Page 84 and 85: OPRM1 A118G and Alcoholism Bart et
Page 86 and 87: COMBINE Study • N = 1383; 9 rando
Page 88 and 89: Rhesus model Ortholog of A118G alle
Page 90 and 91: Results: Heavy Drinking Days 30 75
Page 92 and 93: Endophenotype Endorphin Dependent A
Page 96 and 97: FOR MORE INFORMATION http://www.med
show all

Alcohol

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?